Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

In a report released on May 8, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon, with a price target of $86.00. The company’s sha...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$52.01	+1.56%	860.01K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$52.01	+1.6%	860.01K
3
4
5
6

XENE

XENE

Dividend Overview

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel